Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis - A population pharmacokinetic study

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 502-510

  Hennig, Stefanie ^a   Norris, Ross ^b   Kirkpatrick, Carl M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

Author keywords

Cystic fibrosis; Paediatrics; Population pharmacokinetics; Target concentration intervention; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DEMOGRAPHY; FEMALE; HUMAN; INFANT; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; MODELS, CHEMICAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 40549115710     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03045.x     Document Type: Article

References (31)

1. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinski A, Robertson CF, Grimwood K. Early airway infection, inflammation and lung function in cystic fibrosis. Arch Dis Child 2002 87 : 306 11.
2. Wainwright C, Carlin J, Cooper P. Early infections with Pseudomonas can be cleared in young children with cystic fibrosis. Pediatr Pulm 2002 S24 : 300.
3. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000 16 : 749 67.
4. Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998 46 : 229 36.
5. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004 58 : 8 19.
6. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999 47 : 637 43.
7. Hickling KG, Begg EJ, Perry RE, Atkinson HC, Sharman JR. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med 1991 19 : 1041 7.
8. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984 77 : 657 62.
9. Smyth AR, Tan KH-V, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Knox AJ. Once versus three-times daily regimes of tobramycin treatment for pulmonary exacerbation of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005 365 : 573 8.
10. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999 36 : 89 98.
11. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995 39 : 605 9.
12. Klotz U, Godel A. Once-daily dosing of gentamicin: experience with therapeutic drug monitoring and Bayesian pharmacokinetics. Ther Drug Monit 1994 16 : 534 5.
13. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997 43 : 125 35.
14. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984 100 : 352 7.
15. Phillips JA, Bell S. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Int Med J 2001 31 : 23 6.
16. Massie J, Kohn S, Cranswick N. Once Daily Tobramycin Dosing in Children with Cystic Fibrosis: Are We Using the Right Dose? Cystic Fibrosis Conference. 2000 283.
17. Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis - caution with trough concentrations. J Cyst Fibros 2007 6 : 125 30.
18. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 1999 48 : 9 13.
19. Boeckmann AJ, Sheiner LB, Beal S. NONMEM Users Guide - Part V: Introductory Guide. San Francisco, CA : NONMEM Project Group, University of California at San Francisco, 1994.
20. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005 44 : 1051 65.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
22. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987 155 : 93 9.
23. de Hoog M, Schoemaker RC, Mounton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997 62 : 392 9.
24. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977 22 : 364 70.
25. Bulitta J, Duffull SB, Kinzig-Schnippers M, Holzgrabe U, Stephan U, Soergel F. Cystic Fibrosis Patients are Pharmacokinetically Comparable to Healthy Volunteers. Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA. Abstract 1923 (A-12), 2005.
26. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 32.
27. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006 42 : 601 5.
28. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007 6 : 327 33.
29. Wallace AW, Jones M, Bertino JS Jr. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002 22 : 1077 83.
30. Mohan M, Batty KT, Cooper JA, Wojnar RE, Ilett KF. Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol 2004 58 : 521 7.
31. Greenup LC, Roberts J, Kirkpatrick CMJ. A Comparative Study of the Nomogram vs Bayesian Approaches to Monitoring Aminoglycosides. Proceedings ASCEPT ASM, Melbourne, Australia. Abstract 102, 2005.